Management of Behcet's syndrome
View/ Open
Date
2020-05-01Author
Karadağ, Ömer
Bolek, Ertugrul Cagri
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Abstract
Behcet's syndrome (BS) is a variable vessel vasculitis with heterogeneous clinical features. Skin, mucosa and joint involvement can cause impairment of quality of life but do not cause permanent damage whereas untreated eye, vascular, nervous system and gastrointestinal system involvement can cause serious damage and even death. Management of BS as a multidisciplinary team enables a faster and more accurate diagnosis and well-integrated treatment strategies. Corticosteroids are the mainstay of therapy. Colchicine, AZA, ciclosporin-A, cyclophosphamide, IFN alpha, and tumour necrosis factor alpha inhibitors are other agents used as induction and/or maintenance therapy. Although biologic agents have been increasingly used, there are still unmet needs. Head-to-head comparison studies of some therapeutic options (e.g. TNF inhibitors vs IFN alpha in uveitis) are required. Novel therapeutic agents in the pipeline could change the standard of care for BS in the future.
URI
https://doi.org/10.1093/rheumatology/keaa086https://pubmed.ncbi.nlm.nih.gov/32348509/
https://academic.oup.com/rheumatology/article/59/Supplement_3/iii108/5826894
http://hdl.handle.net/11655/23567
xmlui.mirage2.itemSummaryView.Collections
xmlui.dri2xhtml.METS-1.0.item-citation
Karadag O, Bolek EC. Management of Behcet's syndrome. Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii108-iii117. doi: 10.1093/rheumatology/keaa086. PMID: 32348509.The following license files are associated with this item: